Latest News

Alzheimer’s Blood Tests: How Close Is Routine Screening?

Alzheimer’s Blood Tests: How Close Is Routine Screening?

For decades, confirming Alzheimer’s pathology meant an amyloid PET scan or a lumbar puncture. In 15 months, US regulators have cleared four blood tests that can do a similar job from a blood draw. Yet each Alzheimer’s blood test now on the US market is a diagnostic...

read more

Latest News

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

How GLP-1 Drugs Are Reshaping Anesthesia Practice

How GLP-1 Drugs Are Reshaping Anesthesia Practice

Few classes of medications have changed the perioperative conversation as quickly as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Originally developed primarily for the management of type 2 diabetes, GLP-1 therapy is now widely used for obesity and metabolic...

read more
Designing Resilient Health Systems That Endure

Designing Resilient Health Systems That Endure

The most resilient health systems are not the ones that respond best in times of disruption, they’re the ones designed so that when disruption occurs, care continues and communities remain protected. Systems continue to struggle with workforce shortages, delayed care,...

read more
Weekly News Roundup | 21 September 2026

Weekly News Roundup | 21 September 2026

Life science news 21 September 2026: first US Sanfilippo approval, DESTINY-Lung04 data and a NICE OCD consultation. The FDA approved Fayuvi, the first treatment for Sanfilippo syndrome type A. AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of lung cancer...

read more
Azetukalner NDA Filed as Xenon Pauses Depression Trials

Azetukalner NDA Filed as Xenon Pauses Depression Trials

Xenon Pharmaceuticals submitted the azetukalner NDA to the US Food and Drug Administration on 17 September 2026. The filing covers focal seizures in epilepsy. The same announcement disclosed a voluntary pause on new enrolment in the company’s depression studies. Xenon...

read more
Healthcare Innovation Is Not Always About Something New

Healthcare Innovation Is Not Always About Something New

Healthcare innovation is often associated with something new. A new technology. A new platform. A new device. A new digital service. But healthcare organizations do not always need to add something new to improve care. Sometimes, they need to change something that is...

read more
Clinical Trials Roundup | 18 Sept 2026

Clinical Trials Roundup | 18 Sept 2026

Definium Therapeutics’ DT120 meets its primary endpoint in the Phase 3 Panorama study in generalised anxiety disorder, AstraZeneca’s camizestrant misses its primary endpoint in the Phase III SERENA-4 study in first-line breast cancer, Vera Therapeutics’ atacicept cuts...

read more
Trutakna Two-Year Data Sharpen the IgAN Full Approval Race

Trutakna Two-Year Data Sharpen the IgAN Full Approval Race

Vera Therapeutics has put a two-year kidney function dataset behind its bid for IgAN full approval. On 15 September 2026, the company reported the final efficacy analysis of the Phase 3 ORIGIN 3 trial. The trial tested Trutakna (atacicept-vymj) in adults with primary...

read more
How GLP-1 Drugs Are Reshaping Anesthesia Practice

How GLP-1 Drugs Are Reshaping Anesthesia Practice

Few classes of medications have changed the perioperative conversation as quickly as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Originally developed primarily for the management of type 2 diabetes, GLP-1 therapy is now widely used for obesity and metabolic...

read more
Designing Resilient Health Systems That Endure

Designing Resilient Health Systems That Endure

The most resilient health systems are not the ones that respond best in times of disruption, they’re the ones designed so that when disruption occurs, care continues and communities remain protected. Systems continue to struggle with workforce shortages, delayed care,...

read more
Weekly News Roundup | 21 September 2026

Weekly News Roundup | 21 September 2026

Life science news 21 September 2026: first US Sanfilippo approval, DESTINY-Lung04 data and a NICE OCD consultation. The FDA approved Fayuvi, the first treatment for Sanfilippo syndrome type A. AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of lung cancer...

read more
Azetukalner NDA Filed as Xenon Pauses Depression Trials

Azetukalner NDA Filed as Xenon Pauses Depression Trials

Xenon Pharmaceuticals submitted the azetukalner NDA to the US Food and Drug Administration on 17 September 2026. The filing covers focal seizures in epilepsy. The same announcement disclosed a voluntary pause on new enrolment in the company’s depression studies. Xenon...

read more
Healthcare Innovation Is Not Always About Something New

Healthcare Innovation Is Not Always About Something New

Healthcare innovation is often associated with something new. A new technology. A new platform. A new device. A new digital service. But healthcare organizations do not always need to add something new to improve care. Sometimes, they need to change something that is...

read more
Clinical Trials Roundup | 18 Sept 2026

Clinical Trials Roundup | 18 Sept 2026

Definium Therapeutics’ DT120 meets its primary endpoint in the Phase 3 Panorama study in generalised anxiety disorder, AstraZeneca’s camizestrant misses its primary endpoint in the Phase III SERENA-4 study in first-line breast cancer, Vera Therapeutics’ atacicept cuts...

read more
Trutakna Two-Year Data Sharpen the IgAN Full Approval Race

Trutakna Two-Year Data Sharpen the IgAN Full Approval Race

Vera Therapeutics has put a two-year kidney function dataset behind its bid for IgAN full approval. On 15 September 2026, the company reported the final efficacy analysis of the Phase 3 ORIGIN 3 trial. The trial tested Trutakna (atacicept-vymj) in adults with primary...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Why Pharmaceutical Quality Cannot Be Tested Into a Product

Why Pharmaceutical Quality Cannot Be Tested Into a Product

In pharmaceutical manufacturing, quality control testing is often the point at which a product gets its final analytical assessment. But from my experience in pharmaceutical quality control, one principle is worth emphasizing: QC testing is essential, but QC testing...

read more
Fifty Patients, No Registry: MVA Research Meets in London

Fifty Patients, No Registry: MVA Research Meets in London

Mosaic variegated aneuploidy (MVA) is thought to affect fewer than 50 people worldwide. At that scale, ultra-rare disease research runs into a problem that funding alone does not solve. There is no cohort large enough to randomise. There is often no natural history...

read more
Semaglutide Patent Expiry: What Generics Did to Prices

Semaglutide Patent Expiry: What Generics Did to Prices

The semaglutide patent expiry of March 2026 has now had six months to work. The evidence is uneven. In India, prices fell by up to 70% within weeks. In Canada, generic pens reached pharmacies in May. In China, not one generic has been approved. Readers in the United...

read more
Freeze-Dried Does Not Mean Pathogen-Free

Freeze-Dried Does Not Mean Pathogen-Free

Once concentrated in commercial manufacturing, freeze-drying has entered home kitchens and small food businesses through countertop equipment. That shift has made freeze-dried food safety a live question for small operators. University of Minnesota Extension describes...

read more

Further News

When Will Merck KGaA’s Silence Therapeutics Acquisition Close?

Merck KGaA, Darmstadt, Germany, expects the Silence Therapeutics acquisition to close in the first quarter of 2027. It will pay $20.00 in cash per American depositary share (ADS). That values Silence at about $1.3 billion. The companies announced the deal on 19...

Function Is the Endpoint: Why Aging Research Should Track Reserve

Ask older adults what they fear about aging and few of them name a number. They name the stairs. They name the low chair they cannot get out of, the groceries they cannot carry in from the car, the day they need someone's help to stay at home. That is the question...

An AI Study Without Its Data Is Fiction

Why publish the data at all? My answer comes from my own work. We ran our study not with one AI agent but with several, and later it turned out that the numbers did not match. Without validated AI study data, data that the author answers for in front of the scientific...

Weekly News Roundup | 19 October 2026

Life science news 19 October 2026: three licensing deals, three FDA approvals and two MHRA announcements. Gilead Sciences signed a T-cell engager deal worth up to $1.875bn with Vir Biotechnology. Roche licensed an ALK7 obesity candidate from Rona Therapeutics. The...

FDA Rare Disease Framework: What Will It Change for Developers?

The FDA rare disease framework has not yet changed any rule or approval standard. The agency announced it on 14 October 2026 as an initiative, backed by a white paper. It promises evidence expectations tailored to each rare disease, but it sets no timetable. A public...

Clinical Trial Results 16 October 2026

The clinical trial results 16 October 2026 cover neuroendocrine tumours, bladder, head and neck cancers, pulmonary fibrosis and social anxiety. RayzeBio’s RYZ101 met its primary endpoint at interim analysis in gastroenteropancreatic neuroendocrine tumours. The FDA...

In Vivo Gene Editing Nears Its First FDA Decision: What the Data Shows

In vivo gene editing now has a fixed regulatory date. In April 2026, Intellia Therapeutics reported Phase 3 results for lonvo-z, a therapy that edits DNA inside the body. The company described the result as a global first for in vivo gene editing. In September, the US...

Anktiva NHS Access: Can UK Patients Get It for Bladder Cancer?

Anktiva NHS access has no NICE recommendation behind it. The medicine holds a UK licence, but NICE ended its appraisal in June 2026 because ImmunityBio did not submit evidence.

    Cresset’s Flare AI Client Turns Hours of Work into Minutes

    Scientists can now connect company-approved AI providers such as Claude Code and GitHub Copilot directly to Flare, helping teams set up, execute, and analyze complex computational chemistry workflows in minutes not hours. CAMBRIDGE, UK, 6 October 2026 Drug discovery...

    The National Priority Voucher: Inside the FDA’s Shortest Review Pathway

    Last updated: 15 October 2026. Programme facts checked against FDA sources on that date. A national priority voucher can cut an FDA drug review from around ten months to one or two. The Commissioner’s National Priority Voucher (CNPV) is an FDA pilot programme rather...

    Bispecific T-Cell Engagers in Refractory Autoimmune Disease

    Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...

    Icotrokinra NHS Access: Will the Oral Psoriasis Pill Reach Patients?

    Icotrokinra NHS access has no public timetable. Where the MHRA, NICE and J&J stand on the oral psoriasis pill as of 14 October 2026.

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.